Innovative healthcare interventions for non-communicable diseases

Overview

Funding for early-stage clinical trials validating innovative healthcare interventions—pharmacological or non-pharmacological—for non-communicable diseases (NCDs) such as cardiovascular diseases, diabetes, chronic respiratory diseases, or chronic kidney diseases. Targets researchers, developers, and clinical practitioners aiming to advance treatment and disease management solutions.

Who Can Apply

Legal entities established in eligible countries, including universities, research institutions, hospitals, SMEs, startups, and public bodies. Consortia are expected, with participation from social sciences and humanities (SSH) experts and patient representatives encouraged.

Funding Details

• Maximum grant amount: €10,000,000 per project.
• Funding is provided as a lump sum.
• Co-funding requirements are not specified.

What Is Funded

• Early-stage clinical trials (phase 1 and/or phase 2 for pharmacological interventions) validating novel or refined healthcare interventions for NCDs.
• Development and integration of digital technologies (e.g., AI, wearable devices, virtual human twins) for intervention monitoring and disease management.
• Use and expansion of existing health data infrastructures, biobanks, and registries, with new data managed under FAIR principles.
• Health-economic assessments and Real-World Data (RWD) analysis to support scalability and sustainability.
• Engagement with stakeholders (patients, clinicians, regulators) and national public health authorities.

Technology / Maturity Requirements

• Proposals must demonstrate completed proof-of-concept for clinical safety and efficacy.
• Preclinical research and a draft clinical trial protocol must be finalized at submission.
• Target Technology Readiness Levels (TRL): 4–6.

Key Dates

• Open date: 2027-02-09
• Deadline: 2027-04-12T22:00:00Z

Application Process (High-Level)

• Two-stage evaluation process.

- Stage 1: Blind evaluation of proposals (applicants must not disclose organization names, logos, or personnel details). - Stage 2: Invited applicants submit full proposals, including a dedicated annex for clinical studies.

• Submission via the Funding & Tenders Portal.

Post-Award Obligations

• Participation in networking and joint activities with other funded projects.
• Compliance with FAIR data principles for data management.
• Reporting and dissemination of research advances to policymakers, clinical communities, and patient organizations.
• Potential transfer of ownership or licensing restrictions for up to 4 years post-project.

Geographic Scope & Language

• Eligible countries: EU Member States, Horizon Europe Associated Countries (Norway, Iceland, United Kingdom, Switzerland), and the United States.
• Application language: English.

Notes

• Proposals must address one or more of the following NCDs: cardiovascular diseases, diabetes, chronic respiratory diseases, or chronic kidney diseases.
• Comparative effectiveness studies are excluded.
• Proposals must account for sex, gender, and other stratification criteria (e.g., age, disability, socio-economic status) where relevant.
• Use of Copernicus and/or Galileo/EGNOS is mandatory if satellite-based data/services are employed.